Enveric Biosciences (ENVB) Long-Term Deferred Tax (2016 - 2026)

Enveric Biosciences (ENVB) posted Long-Term Deferred Tax of $26438.0 for Q1 2026, down 98.35% sequentially from $1.6 million in Q4 2021.

Enveric Biosciences (ENVB) Long-Term Deferred Tax (2016 - 2026) Analysis & Trends

Enveric Biosciences has reported Long-Term Deferred Tax for 7 years, with the latest figure at $26438.0 in Q1 2026.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $26438.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26438.0 (changed N/A YoY) and the FY2021 annual result came in at $1.6 million, changed N/A from the prior year.
Long-Term Deferred Tax slipped to $26438.0 in Q1 2026 per ENVB's latest filing, from $1.6 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $26438.0 in Q1 2026 and troughed at $26438.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.36 Bn	26.52 Bn	-
10	Enveric Biosciences	5.72 Mn	-2.57 Mn	-

Download Data